The Company is a solo, general neurology practice operating from a single office location (approximately 3,000 sq ft) in the greater Houston, Texas metro area. The practice treats a broad range of neurologic conditions, including headaches and migraines, insomnia, sleep apnea, transient ischemic attacks (TIA), and Parkinson's disease, and performs in-house diagnostic testing — electroencephalogram (EEG) and electromyography/nerve conduction studies (EMG/NCV) — rather than referring these studies out to a third party. The treating physician maintains hospital affiliations supporting continuity of care for patients requiring inpatient consultation, and the practice serves patients in English, Spanish, and Hindi. The Company's EMR holds approximately 4,000 patients.
The Company generated $735,428 in gross revenue in the 2025 calendar year, up from $615,317 in 2024 and $656,262 in 2023, with 2026 tracking to a similar run-rate through the first six months of the year. The practice's payor mix is predominantly commercial insurance and Medicare, contracted through IPA and physician-group arrangements, with a portion of contracts held directly in the treating physician's own name. The Company carries no outstanding business debt.
IMPORTANT — CLOSURE TIMELINE: The treating physician is unable to continue practicing full time and the clinic must close as of August 31, 2026. This is a time-sensitive opportunity: a buyer who can move has the best chance of preserving continuity with the existing ~4,000-patient panel. The listing price reflects the practice's underlying financial performance as a going concern; the Seller and Broker anticipate this price may be adjusted to reflect the compressed transition timeline as needed.
